Cargando…
SAT-356 Reversible Suppression of Serum 1,25-Dihydroxyvitamin D in Williams Syndrome
Background: Hypercalcemia has been reported in 5% to 50% of patients with Williams syndrome; however, observations about the role of 1,25-dihydroxyvitamin D in hypercalcemia related to Williams syndrome have been contradictory. Objective: The objective was to investigate the mineral metabolism in an...
Autores principales: | Torchinsky, Michael Yuri, Bugaieski, Eric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207367/ http://dx.doi.org/10.1210/jendso/bvaa046.010 |
Ejemplares similares
-
Characteristics of Serum Ratios of 1,25-Dihydroxyvitamin D to 25-Hydroxyvitamin D for Assessment of Bone Metabolism
por: Yamamoto, Koichiro, et al.
Publicado: (2021) -
SAT257 Efficacy Of Oral Cinacalcet In Non-PTH Non-Malignant Hypercalcemia From Excess 1,25 Dihydroxyvitamin D
por: Mohan, Sneha, et al.
Publicado: (2023) -
MON-374 Management of 1,25-dihydroxyvitamin D (1,25-OHD) Mediated Hypercalcemia of Unknown Etiology
por: Menon, Sruthi, et al.
Publicado: (2020) -
MON-388 Total and Free 1,25dihydroxyvitamin D Levels in Postmenopausal Patients with Primary Hyperparathyroidism
por: Meng, Lingqiong, et al.
Publicado: (2020) -
LBSAT131 Extended-release Calcifediol Reduced Ipth And Normalized 1,25-dihydroxyvitamin D In Esrd.
por: Ashfaq, Akhtar, et al.
Publicado: (2022)